Cleared Traditional

K770882 - ULTRAZYME PLUS GPT

K770882 is the FDA 510(k) clearance for ULTRAZYME PLUS GPT by Harleco. It is a Class 1 Chemistry device (product code CKA) cleared through the Traditional 510(k) pathway after a 59-day FDA review.

K770882 · Harleco · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1977
Decision
59d
Days
Class 1
Risk

K770882 is an FDA 510(k) clearance for the ULTRAZYME PLUS GPT. Classified as Nadh Oxidation/nad Reduction, Alt/sgpt (product code CKA), Class I - General Controls.

Submitted by Harleco (Mchenry, US). The FDA issued a Cleared decision on July 14, 1977 after a review of 59 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1030 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Harleco devices

Submission Details

510(k) Number K770882 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 16, 1977
Decision Date July 14, 1977
Days to Decision 59 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
29d faster than avg
Panel avg: 88d · This submission: 59d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code CKA Nadh Oxidation/nad Reduction, Alt/sgpt
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1030
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - CKA Nadh Oxidation/nad Reduction, Alt/sgpt

All 98
Devices cleared under the same product code (CKA) and FDA review panel - the closest regulatory comparables to K770882.
GEMSAEC APPLI. FOR ULTRAZYME PLUS GPT
K772030 · Harleco · Nov 1977
DYNAZYME II GPT 340
K771152 · J.T. Baker Chemical Co. · Nov 1977
MULTISTAT III ALANINE AMINOTRANSFERASE
K771466 · Instrumentation Laboratory CO · Sep 1977
GEMENI GPT (ALT) ASSAY
K761269 · Electro-Nucleonics Laboratories, Inc. · Dec 1976
NDC#12739-0010-1 C-ZYME GPT
K760194 · Coulter Electronics, Inc. · Aug 1976